Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.

Tan B, Dong S, Shepard RL, Kays L, Roth KD, Geeganage S, Kuo MS, Zhao G.

J Biol Chem. 2015 Jun 19;290(25):15812-24. doi: 10.1074/jbc.M114.632141. Epub 2015 May 5.

2.

Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.

Pratt SE, Durland-Busbice S, Shepard RL, Donoho GP, Starling JJ, Wickremsinhe ER, Perkins EJ, Dantzig AH.

Mol Cancer Ther. 2013 Apr;12(4):481-90. doi: 10.1158/1535-7163.MCT-12-0654. Epub 2013 Jan 31.

3.

Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.

Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH.

Clin Cancer Res. 2013 Mar 1;19(5):1159-68. doi: 10.1158/1078-0432.CCR-12-1184. Epub 2013 Jan 16.

4.

Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.

Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL, Roth K, Zhai Y, Huss K, Kuo MS, Gillig J, Parthasarathy S, Burkholder TP, Smith MC, Geeganage S, Zhao G.

J Biol Chem. 2013 Feb 1;288(5):3500-11. doi: 10.1074/jbc.M112.394510. Epub 2012 Dec 13.

5.

Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.

Perry WL 3rd, Shepard RL, Sampath J, Yaden B, Chin WW, Iversen PW, Jin S, Lesoon A, O'Brien KA, Peek VL, Rolfe M, Shyjan A, Tighe M, Williamson M, Krishnan V, Moore RE, Dantzig AH.

Cancer Res. 2005 Aug 1;65(15):6593-600.

6.

The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites.

Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH.

Mol Cancer Ther. 2005 May;4(5):855-63.

7.

Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.

Dantzig AH, Shepard RL, Pratt SE, Tabas LB, Lander PA, Ma L, Paul DC, Williams DC, Peng SB, Slapak CA, Godinot N, Perry WL 3rd.

Biochem Pharmacol. 2004 Mar 15;67(6):1111-21.

PMID:
15006547
8.

Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells.

Sampath J, Long PR, Shepard RL, Xia X, Devanarayan V, Sandusky GE, Perry WL 3rd, Dantzig AH, Williamson M, Rolfe M, Moore RE.

Am J Pathol. 2003 Nov;163(5):1781-90.

9.

Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.

Shepard RL, Cao J, Starling JJ, Dantzig AH.

Int J Cancer. 2003 Jan 1;103(1):121-5.

10.

Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione.

Qian YM, Grant CE, Westlake CJ, Zhang DW, Lander PA, Shepard RL, Dantzig AH, Cole SP, Deeley RG.

J Biol Chem. 2002 Sep 20;277(38):35225-31. Epub 2002 Jul 22.

11.

GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain.

Mao Q, Qiu W, Weigl KE, Lander PA, Tabas LB, Shepard RL, Dantzig AH, Deeley RG, Cole SP.

J Biol Chem. 2002 Aug 9;277(32):28690-9. Epub 2002 May 28.

12.

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):974-81.

PMID:
11961114
13.

Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.

Mol Pharmacol. 2002 May;61(5):964-73.

PMID:
11961113
14.

Cytotoxic responses to aromatic ring and configurational variations in alpha-conidendrin, podophyllotoxin, and sikkimotoxin derivatives.

Dantzig A, LaLonde RT, Ramdayal F, Shepard RL, Yanai K, Zhang M.

J Med Chem. 2001 Jan 18;44(2):180-5.

PMID:
11170627
15.

Evaluation of an in vitro coculture model for the blood-brain barrier: comparison of human umbilical vein endothelial cells (ECV304) and rat glioma cells (C6) from two commercial sources.

Scism JL, Laska DA, Horn JW, Gimple JL, Pratt SE, Shepard RL, Dantzig AH, Wrighton SA.

In Vitro Cell Dev Biol Anim. 1999 Nov-Dec;35(10):580-92.

PMID:
10614867
16.

Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146.

Norman BH, Dantzig AH, Kroin JS, Law KL, Tabas LB, Shepard RL, Palkowitz AD, Hauser KL, Winter MA, Sluka JP, Starling JJ.

Bioorg Med Chem Lett. 1999 Dec 6;9(23):3381-6.

PMID:
10612603
17.

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA.

J Pharmacol Exp Ther. 1999 Aug;290(2):854-62.

PMID:
10411602
18.

Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.

Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH.

Biochem Pharmacol. 1998 Sep 15;56(6):719-27.

PMID:
9751076
19.

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF, Dantzig AH.

Adv Enzyme Regul. 1997;37:335-47.

PMID:
9381979
20.

Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ.

Cancer Res. 1996 Sep 15;56(18):4171-9.

21.

Association of intestinal peptide transport with a protein related to the cadherin superfamily.

Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, Jenkins IL, Duckworth DC, Sportsman JR, Mackensen D, Rosteck PR Jr, et al.

Science. 1994 Apr 15;264(5157):430-3.

PMID:
8153632
22.

Bioavailability to rats of iron from fortified grain amaranth.

Ologunde MO, Morris JB, Shepard RL, Afolabi AO, Oke OL.

Plant Foods Hum Nutr. 1994 Apr;45(3):191-201.

PMID:
8052576
23.

Expanded role for fine needle aspiration of the prostate. A study of 335 specimens.

Stilmant MM, Freedlund MC, de las Morenas A, Shepard RL, Oates RD, Siroky MB.

Cancer. 1989 Feb 1;63(3):583-92.

PMID:
2912534
24.

The role of ammonia toxicity in the post transurethral prostatectomy syndrome.

Shepard RL, Kraus SE, Babayan RK, Siroky MB.

Br J Urol. 1987 Oct;60(4):349-51.

PMID:
3690208

Supplemental Content

Loading ...
Support Center